Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX - Get Free Report) shares crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $1.73 and traded as high as $5.23. Cumberland Pharmaceuticals shares last traded at $4.60, with a volume of 297,831 shares.
Analyst Ratings Changes
Separately, StockNews.com initiated coverage on shares of Cumberland Pharmaceuticals in a research report on Friday. They set a "hold" rating for the company.
Read Our Latest Analysis on Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Price Performance
The company has a market cap of $72.31 million, a price-to-earnings ratio of -6.69 and a beta of 0.12. The company has a fifty day simple moving average of $2.78 and a two-hundred day simple moving average of $1.80. The company has a quick ratio of 0.99, a current ratio of 1.13 and a debt-to-equity ratio of 0.41.
About Cumberland Pharmaceuticals
(
Get Free Report)
Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
Featured Articles
Before you consider Cumberland Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cumberland Pharmaceuticals wasn't on the list.
While Cumberland Pharmaceuticals currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
